Search: projects

Country:	All Africa    Benin    Botswana    Burkina Faso    Burundi    Cameroon    Cap Vert    Chad    Comores    Congo Brazzaville    Congo RDC    Djibouti    Ethiopia    Gabon    Gambia    Ghana    Guinea    Guinea Bissau    Guinea Conakry    Ivory Coast    Kenya    Lesotho    Liberia    Madagascar    Malawi    Mali    Mauritania    Mauritius    Mozambique    Namibia    Niger    Nigeria    Rwanda    Senegal    Seychelles    Sierra Leone    South Africa    Sudan    Swaziland    Tanzania / Zanzibar    Togo    Uganda    Zambia    ZimbabweAsia    Afghanistan    Armenia    Azerbaijan    Bangladesh    Bhutan    Cambodia    China    India    Indonesia    Kazachstan    Kyrgyzstan    Laos    Moldova    Mongolia    Myanmar    Tajikistan    Thailand    The Philippines    VietnamCaribbean    Antigua and Barbuda    Bahamas    Barbados    Caribbean Partnership    Cuba    Dominica    Dominican Republic    Grenada    Haiti    Jamaica    Montserrat    St. Kitts and Nevis    St. Lucia    St. Vincent and the Grenadines    Trinidad & TobagoEurope    Austria    Belgium    Denmark    France    Germany    Moldova    Montenegro    Romania    Switzerland    The Netherlands    TurkeyGlobal    GlobalLatin America    Belize    Bolivia    Costa Rica    Ecuador    El Salvador    Guatemala    Guyana    Honduras    Nicaragua    Panama    Peru    SurinameMediterranean    Algeria    Egypt    Libya    Morocco    TunisiaMiddle East    Jordan    Palestine    Syria    YemenPacific    East Timor    Papua New Guinea    Solomon Islands
Field of expertise:	All Health Economics and Financing    Cost-effectiveness Studies    Costing Studies    Health Expenditure Review    Health Financing and Provider Payment    Health Insurance    National Health AccountsHealth Programmes    Basic Health Services    HIV-AIDS-STI-TB    Hospital Services    Other Health Programmes    Reproductive HealthHealth System    Health Information System / Epidemiology / Operational Research    Health Policy and Policy Dialogue    Health Sector Reform    Health Sector Review or Health Sector Diagnosis    Monitoring and Evaluation    Planning, Organisation and Management    Public Private Partnership    Sector Wide Approach (SWAp)    Training and Human Resource DevelopmentPharmaceutical Sector    Access to Medicine Campaigns    Drug Pricing Studies    Drug Regulatory Authority Support    Drug Supply Management System Strengthening    Essential Drugs Programme Support    Essential Medicines Financing    Increasing Transparency In Public And Private Pharmaceutical Markets    Medical Store Evaluation    National Medicines Policy Development    Pharmaceutical Sector Review    Procurement and Tender Support    Public Private Partnership Interventions    Quantification of Essential Drug Needs    Rational Use Surveys    Selection of Essential Medicines    Training and Human Resource DevelopmentProject Cycle    Appraisal    Identification and Formulation    Long Term Technical Assistance    Monitoring and Evaluation
Assignment:
Client:
Description:
Order by:	Assignment Client Year Country

---

Assignment:	Preparation Danida Health Sector Programme Support Phase III
Client:	Danida
Country:	Tanzania / Zanzibar
Fields of expertise:	Basic Health Services, Drug Supply Management System Strengthening, Health Expenditure Review, Health Information System / Epidemiology / Operational Research, Health Policy and Policy Dialogue, Health Sector Reform, Health Sector Review or Health Sector Diagnosis, Hospital Services, Identification and Formulation, Pharmaceutical Sector Review, Planning, Organisation and Management, Public Private Partnership Interventions, Rational Use Surveys, Sector Wide Approach (SWAp)
Description:	Narrative Description of Project: Main objectives of Phase III: Development Objective: to improve the health and well being of all Tanzanians, with a focus on those at risk, and to encourage the health system to be more responsive to the needs of the people. Specific Objectives of Danish support: Improve comprehensive planning and delivery of quality health services – including the private sector at district level- with a focus on the major diseases including HIV/AIDS, the poor and vulnerable as well as on gender aspects. Improve the capacity of the private sector to contribute to systems development and participate in policy dialogue Improve drug supply and the rational use of drugs Improve hospital management on district and regional level Improve the information systems relevant to the health sector Description of Actual Services Provided: Study of background documents relying on existing documentation and with very limited primary data gathering; meetings with key officials from government and donor partners, field trips and workshops. A detailed report with attention to cross-cutting issues and priority themes., management and organisation, financial management and procurement, monitoring, reporting, reviews and evaluation, assessment of key assumptions and risks, component implementation plan, and recommendations.
Year:	2003

Assignment:	Review of the Drug Provision System (indent system)
Client:	Danida
Country:	Tanzania / Zanzibar
Fields of expertise:	Drug Supply Management System Strengthening, Essential Drugs Programme Support, Essential Medicines Financing, Monitoring and Evaluation, Planning, Organisation and Management, Rational Use Surveys
Description:	Narrative Description of Project: The objectives of the review are to carry out a thorough assessment of the indent system for drugs distribution as piloted in Morogoro region under HSPS and make recommendations for the further implementation of a pull system in Tanzania. Description of Actual Services Provided: The team performed the following review: Assessment of the initial design and the operational version of the Indent System; Assessment of the actual implementation of the system package with regard to its adequacy for implementation in other regions; Assessment of the impact of the system; Assessment of the financial aspects; Assessment of the system’s potential to respond to the health reform target of delegation responsibilities for the planning and execution of drug supply at PHC level; Assessment of quality of the data acquired via the system as basis for preparation of drug sector policies; Assessment of the system’s potential to promote rational use of drugs; Analysis and comparison of the costs and control mechanism of the previous “push” system of standard kits versus the Indent System as a “pull” system; Analysis and assessment of options for further implementation of a “pull system” and recommend on replication and adjustments of the present system. Assess and quantify the need for further external financial and technical assistance. Identify the need for socio-economic assessment of the system after introduction of socio-sharing for drugs.
Year:	2000

Assignment:	Medicines Transparency Alliance (MeTA)
Client:	DFID
Country:	Ghana
Fields of expertise:	Access to Medicine Campaigns, Drug Pricing Studies, Drug Regulatory Authority Support, Drug Supply Management System Strengthening, Essential Drugs Programme Support, Essential Medicines Financing, Increasing Transparency In Public And Private Pharmaceutical Markets, National Medicines Policy Development, Procurement and Tender Support, Public Private Partnership Interventions, Rational Use Surveys, Training and Human Resource Development
Description:	Narrative description of Project: MeTA is a new multi-stakeholder approach for increasing transparency around the selection, procurement, sale and distribution of medicines in Low Income Countries, thereby strengthening governance and encouraging responsible business practices. The MeTA goal is to ensure access to affordable essential drugs in developing countries (MDG 8, target 17). The initiative us being supported financially by DFID during its present Phase One. MeTA brings together, at both the international and national levels, a diverse group of people with an interest in the pharmaceutical sector (stakeholders) to find ways to improve information flows, and increase transparency and accountability about the selection, regulation, procurement, sale, distribution and use of medicines in developing countries. By doing so, MeTA will improve how decisions are made about medicines, improve the way they are purchased and supplied, encourage innovative and responsible business practices, and increase the voice of patients and consumers. Description of actual services provided by your staff within the assignment: The MeTA International Secretariat is tasked to help to support the implementation of MeTA in 7 pilot countries, through facilitating support for the evolution and effective functioning of the National Secretariats, National Multi-Stakeholder Group (NMSGs), and implementation of work plans. Following the establishment of country MeTA structures, the International MeTA Secretariat provides further support to the pilot countries including: Supporting countries to extract and collate data on medicine quality, availability and pricing along the supply chain; Supporting countries to undertake studies assessing the level of transparency and good governance in medicines regulation and procurement; Working with countries to produce country-specific MeTA reports, which would collate data and further analyse and contextualise issues related to medicine quality, availability and price, and to disseminate these reports through the media and public interest groups; as well as exploring policy options and support needed for implementation e.g. of report recommendations. Assist countries in using the data collated through MeTA on medicine policies and regulation as well as quality, availability and prices to try to promote relevant good practice and policy changes to improve access to medicines. HERA contracted staff are responsible for the provision of country specific support under META. Pilot countries are: Ghana, Uganda, Zambia, the Philippines, Jordan, Kyrgyzstan and Peru.
Year:	2008 - 2010

Assignment:	Medicines Transparency Alliance (MeTA)
Client:	DFID
Country:	Kyrgyzstan
Fields of expertise:	Access to Medicine Campaigns, Drug Pricing Studies, Drug Regulatory Authority Support, Drug Supply Management System Strengthening, Essential Drugs Programme Support, Essential Medicines Financing, Increasing Transparency In Public And Private Pharmaceutical Markets, National Medicines Policy Development, Public Private Partnership Interventions, Rational Use Surveys, Training and Human Resource Development
Description:	Narrative description of Project: MeTA is a new multi-stakeholder approach for increasing transparency around the selection, procurement, sale and distribution of medicines in Low Income Countries, thereby strengthening governance and encouraging responsible business practices. The MeTA goal is to ensure access to affordable essential drugs in developing countries (MDG 8, target 17). The initiative us being supported financially by DFID during its present Phase One. MeTA brings together, at both the international and national levels, a diverse group of people with an interest in the pharmaceutical sector (stakeholders) to find ways to improve information flows, and increase transparency and accountability about the selection, regulation, procurement, sale, distribution and use of medicines in developing countries. By doing so, MeTA will improve how decisions are made about medicines, improve the way they are purchased and supplied, encourage innovative and responsible business practices, and increase the voice of patients and consumers. Description of actual services provided by your staff within the assignment: The MeTA International Secretariat is tasked to help to support the implementation of MeTA in 7 pilot countries, through facilitating support for the evolution and effective functioning of the National Secretariats, National Multi-Stakeholder Group (NMSGs), and implementation of work plans. Following the establishment of country MeTA structures, the International MeTA Secretariat provides further support to the pilot countries including: Supporting countries to extract and collate data on medicine quality, availability and pricing along the supply chain; Supporting countries to undertake studies assessing the level of transparency and good governance in medicines regulation and procurement; Working with countries to produce country-specific MeTA reports, which would collate data and further analyse and contextualise issues related to medicine quality, availability and price, and to disseminate these reports through the media and public interest groups; as well as exploring policy options and support needed for implementation e.g. of report recommendations. Assist countries in using the data collated through MeTA on medicine policies and regulation as well as quality, availability and prices to try to promote relevant good practice and policy changes to improve access to medicines. HERA contracted staff are responsible for the provision of country specific support under META. Pilot countries are: Ghana, Uganda, Zambia, the Philippines, Jordan, Kyrgyzstan and Peru.
Year:	2008 - 2010

Assignment:	Medicines Transparency Alliance (MeTA)
Client:	DFID
Country:	Peru
Fields of expertise:	Access to Medicine Campaigns, Drug Pricing Studies, Drug Regulatory Authority Support, Drug Supply Management System Strengthening, Essential Drugs Programme Support, Essential Medicines Financing, Increasing Transparency In Public And Private Pharmaceutical Markets, National Medicines Policy Development, Public Private Partnership Interventions, Rational Use Surveys, Training and Human Resource Development
Description:	Narrative description of Project: MeTA is a new multi-stakeholder approach for increasing transparency around the selection, procurement, sale and distribution of medicines in Low Income Countries, thereby strengthening governance and encouraging responsible business practices. The MeTA goal is to ensure access to affordable essential drugs in developing countries (MDG 8, target 17). The initiative us being supported financially by DFID during its present Phase One. MeTA brings together, at both the international and national levels, a diverse group of people with an interest in the pharmaceutical sector (stakeholders) to find ways to improve information flows, and increase transparency and accountability about the selection, regulation, procurement, sale, distribution and use of medicines in developing countries. By doing so, MeTA will improve how decisions are made about medicines, improve the way they are purchased and supplied, encourage innovative and responsible business practices, and increase the voice of patients and consumers. Description of actual services provided by your staff within the assignment: The MeTA International Secretariat is tasked to help to support the implementation of MeTA in 7 pilot countries, through facilitating support for the evolution and effective functioning of the National Secretariats, National Multi-Stakeholder Group (NMSGs), and implementation of work plans. Following the establishment of country MeTA structures, the International MeTA Secretariat provides further support to the pilot countries including: Supporting countries to extract and collate data on medicine quality, availability and pricing along the supply chain; Supporting countries to undertake studies assessing the level of transparency and good governance in medicines regulation and procurement; Working with countries to produce country-specific MeTA reports, which would collate data and further analyse and contextualise issues related to medicine quality, availability and price, and to disseminate these reports through the media and public interest groups; as well as exploring policy options and support needed for implementation e.g. of report recommendations. Assist countries in using the data collated through MeTA on medicine policies and regulation as well as quality, availability and prices to try to promote relevant good practice and policy changes to improve access to medicines. HERA contracted staff are responsible for the provision of country specific support under META. Pilot countries are: Ghana, Uganda, Zambia, the Philippines, Jordan, Kyrgyzstan and Peru.
Year:	2008 - 2010

Assignment:	Medicines Transparency Alliance (MeTA)
Client:	DFID
Country:	The Philippines
Fields of expertise:	Access to Medicine Campaigns, Drug Pricing Studies, Drug Regulatory Authority Support, Drug Supply Management System Strengthening, Essential Drugs Programme Support, Essential Medicines Financing, Increasing Transparency In Public And Private Pharmaceutical Markets, National Medicines Policy Development, Public Private Partnership Interventions, Rational Use Surveys, Training and Human Resource Development
Description:	Narrative description of Project: MeTA is a new multi-stakeholder approach for increasing transparency around the selection, procurement, sale and distribution of medicines in Low Income Countries, thereby strengthening governance and encouraging responsible business practices. The MeTA goal is to ensure access to affordable essential drugs in developing countries (MDG 8, target 17). The initiative us being supported financially by DFID during its present Phase One. MeTA brings together, at both the international and national levels, a diverse group of people with an interest in the pharmaceutical sector (stakeholders) to find ways to improve information flows, and increase transparency and accountability about the selection, regulation, procurement, sale, distribution and use of medicines in developing countries. By doing so, MeTA will improve how decisions are made about medicines, improve the way they are purchased and supplied, encourage innovative and responsible business practices, and increase the voice of patients and consumers. Description of actual services provided by your staff within the assignment: The MeTA International Secretariat is tasked to help to support the implementation of MeTA in 7 pilot countries, through facilitating support for the evolution and effective functioning of the National Secretariats, National Multi-Stakeholder Group (NMSGs), and implementation of work plans. Following the establishment of country MeTA structures, the International MeTA Secretariat provides further support to the pilot countries including: Supporting countries to extract and collate data on medicine quality, availability and pricing along the supply chain; Supporting countries to undertake studies assessing the level of transparency and good governance in medicines regulation and procurement; Working with countries to produce country-specific MeTA reports, which would collate data and further analyse and contextualise issues related to medicine quality, availability and price, and to disseminate these reports through the media and public interest groups; as well as exploring policy options and support needed for implementation e.g. of report recommendations. Assist countries in using the data collated through MeTA on medicine policies and regulation as well as quality, availability and prices to try to promote relevant good practice and policy changes to improve access to medicines. HERA contracted staff are responsible for the provision of country specific support under META. Pilot countries are: Ghana, Uganda, Zambia, the Philippines, Jordan, Kyrgyzstan and Peru.
Year:	2008 - 2010

Assignment:	Medicines Transparency Alliance (MeTA)
Client:	DFID
Country:	Uganda
Fields of expertise:	Access to Medicine Campaigns, Drug Pricing Studies, Drug Regulatory Authority Support, Drug Supply Management System Strengthening, Essential Drugs Programme Support, Essential Medicines Financing, Increasing Transparency In Public And Private Pharmaceutical Markets, National Medicines Policy Development, Public Private Partnership Interventions, Rational Use Surveys, Training and Human Resource Development
Description:	Narrative description of Project: MeTA is a new multi-stakeholder approach for increasing transparency around the selection, procurement, sale and distribution of medicines in Low Income Countries, thereby strengthening governance and encouraging responsible business practices. The MeTA goal is to ensure access to affordable essential drugs in developing countries (MDG 8, target 17). The initiative us being supported financially by DFID during its present Phase One. MeTA brings together, at both the international and national levels, a diverse group of people with an interest in the pharmaceutical sector (stakeholders) to find ways to improve information flows, and increase transparency and accountability about the selection, regulation, procurement, sale, distribution and use of medicines in developing countries. By doing so, MeTA will improve how decisions are made about medicines, improve the way they are purchased and supplied, encourage innovative and responsible business practices, and increase the voice of patients and consumers. Description of actual services provided by your staff within the assignment: The MeTA International Secretariat is tasked to help to support the implementation of MeTA in 7 pilot countries, through facilitating support for the evolution and effective functioning of the National Secretariats, National Multi-Stakeholder Group (NMSGs), and implementation of work plans. Following the establishment of country MeTA structures, the International MeTA Secretariat provides further support to the pilot countries including: Supporting countries to extract and collate data on medicine quality, availability and pricing along the supply chain; Supporting countries to undertake studies assessing the level of transparency and good governance in medicines regulation and procurement; Working with countries to produce country-specific MeTA reports, which would collate data and further analyse and contextualise issues related to medicine quality, availability and price, and to disseminate these reports through the media and public interest groups; as well as exploring policy options and support needed for implementation e.g. of report recommendations. Assist countries in using the data collated through MeTA on medicine policies and regulation as well as quality, availability and prices to try to promote relevant good practice and policy changes to improve access to medicines. HERA contracted staff are responsible for the provision of country specific support under META. Pilot countries are: Ghana, Uganda, Zambia, the Philippines, Jordan, Kyrgyzstan and Peru.
Year:	2008 - 2010

Assignment:	Medicines Transparency Alliance (MeTA)
Client:	DFID
Country:	Zambia
Fields of expertise:	Access to Medicine Campaigns, Drug Pricing Studies, Drug Regulatory Authority Support, Drug Supply Management System Strengthening, Essential Drugs Programme Support, Essential Medicines Financing, Increasing Transparency In Public And Private Pharmaceutical Markets, National Medicines Policy Development, Public Private Partnership Interventions, Rational Use Surveys, Training and Human Resource Development
Description:	Narrative description of Project: MeTA is a new multi-stakeholder approach for increasing transparency around the selection, procurement, sale and distribution of medicines in Low Income Countries, thereby strengthening governance and encouraging responsible business practices. The MeTA goal is to ensure access to affordable essential drugs in developing countries (MDG 8, target 17). The initiative us being supported financially by DFID during its present Phase One. MeTA brings together, at both the international and national levels, a diverse group of people with an interest in the pharmaceutical sector (stakeholders) to find ways to improve information flows, and increase transparency and accountability about the selection, regulation, procurement, sale, distribution and use of medicines in developing countries. By doing so, MeTA will improve how decisions are made about medicines, improve the way they are purchased and supplied, encourage innovative and responsible business practices, and increase the voice of patients and consumers. Description of actual services provided by your staff within the assignment: The MeTA International Secretariat is tasked to help to support the implementation of MeTA in 7 pilot countries, through facilitating support for the evolution and effective functioning of the National Secretariats, National Multi-Stakeholder Group (NMSGs), and implementation of work plans. Following the establishment of country MeTA structures, the International MeTA Secretariat provides further support to the pilot countries including: Supporting countries to extract and collate data on medicine quality, availability and pricing along the supply chain; Supporting countries to undertake studies assessing the level of transparency and good governance in medicines regulation and procurement; Working with countries to produce country-specific MeTA reports, which would collate data and further analyse and contextualise issues related to medicine quality, availability and price, and to disseminate these reports through the media and public interest groups; as well as exploring policy options and support needed for implementation e.g. of report recommendations. Assist countries in using the data collated through MeTA on medicine policies and regulation as well as quality, availability and prices to try to promote relevant good practice and policy changes to improve access to medicines. HERA contracted staff are responsible for the provision of country specific support under META. Pilot countries are: Ghana, Uganda, Zambia, the Philippines, Jordan, Kyrgyzstan and Peru.
Year:	2008 - 2010

Assignment:	Pharmaceutical System Assessment
Client:	Ministry of Health
Country:	Lesotho
Fields of expertise:	Essential Drugs Programme Support, Essential Medicines Financing, National Medicines Policy Development, Pharmaceutical Sector Review, Procurement and Tender Support, Public Private Partnership Interventions, Rational Use Surveys, Training and Human Resource Development
Description:	Narrative Description of Project: To carry out a comprehensive review of the Pharmaceutical systems in Lesotho, to make proposals and assist the Pharmaceutical Department to define and begin to implement a programme of reforms. Description of Actual Services Provided: General assessment of pharmaceutical management (MOHSW pharmaceuticals dept, CHAL, LPC, NDSO) Policy review: review of draft National Drug Policy Review of procurement process Assess methodology of procuring drugs Assess adequacy of present QA system Drug financing: review sources of funding, assess management of drug budget Pharmaceutical information system Rational Drug use Preparation for drug registration Human resources Private-public sector: analysis capacity/efficiency ; price comparison Capacity building Assist implementation
Year:	2002 - 2003

Assignment:	Diagnosis and reorganisation of the pharmaceutical sector
Client:	World Bank
Country:	Rwanda
Fields of expertise:	Drug Regulatory Authority Support, Drug Supply Management System Strengthening, Essential Drugs Programme Support, Essential Medicines Financing, Health Sector Reform, Medical Store Evaluation, National Medicines Policy Development, Pharmaceutical Sector Review, Planning, Organisation and Management, Quantification of Essential Drug Needs, Rational Use Surveys, Selection of Essential Medicines, Training and Human Resource Development
Description:	Narrative Description of Project: Diagnosis and reorganisation of the pharmaceutical sector in Rwanda (public and private sector). Development of a national policy and legislation for the pharmaceutical sector. Institutional strengthening of the Pharmaceutical Department of the Ministry of Health. Technical and organisational proposals for a new structure for a national central medical store. Quantification of the national needs for essential drugs. Development of the strategies for procurement, supply, storing and distribution of the essential drugs. Proposal for a diagnostic and treatment standard. Strategies for the registration, quality control and rational use of drugs. Development of financial policies for drugs (custom duties, price regulation, etc.). Proposal for the financing of the development plan of the pharmaceutical sector. Description of Actual Services Provided: Responsible for a detailed analysis of the pharmaceutical sector, including policy, legislation, provision and supply of drugs, drug needs by level and by sector, drug use, drug registration, drug financing aspects. Provided assistance to the Ministry of Health in all the above fields to develop proposals to reform. Assisted the Ministry of Health in developing a new central medical stores structure as a parastatal organisation. Developed a financial plan for all proposed reforms. Consensus development at a national and international workshop where proposals for reform have been presented. The actual and functional national central medical store in Kigali is based on the feasibility study and the technical proposals made by HERA-CDP.
Year:	1993 - 1994

Assignment:	Review of the Pharmaceutical Sector
Client:	World Bank - Ministry of Health
Country:	Kenya
Fields of expertise:	Drug Regulatory Authority Support, Drug Supply Management System Strengthening, Essential Drugs Programme Support, Health Policy and Policy Dialogue, Health Sector Reform, Health Sector Review or Health Sector Diagnosis, Monitoring and Evaluation, National Medicines Policy Development, Pharmaceutical Sector Review, Procurement and Tender Support, Quantification of Essential Drug Needs, Rational Use Surveys
Description:	Narrative description of Project: The Government of Kenya, with support from its partners including the World Bank, has committed itself to a series of reform efforts in the health sector. As part of this , the MOH commissioned a comprehensive review of the pharmaceutical sector. The review was contracted in 4 different consultancies of which HERA completed 3 parts: Consultancy for Evaluation of Pharmaceutical Access in Kenya, including an Institutional Capacity Assessment of the MOH and KEMSA Consultancy for Evaluating/Improving Quality Assurance and Sustainability in the Medical Supplies Sub-sector in Kenya Consultancy to strengthen the logistics Management and the Rational Use of Drugs in Kenya. Description of actual services provided: Evaluation of Pharmaceutical Access in Kenya: Description of geographical, physical and financial access to drugs in Kenya, particularly for the diseases of poverty, in both public and private sectors; Evaluation of the structure, functioning and outcomes of the existing drug supply systems (including the procurement, warehousing and distribution of drugs to all levels of the health care system); Assessment of the structure, functioning and outcomes of the existing pharmaceutical financing and pricing systems from an efficiency and equity perspective; Development of alternative proposals for efficient and equitable systems of drug supply management, financing and pricing. Evaluating/ Improving Quality Assurance and Sustainability in the Medical Supplies Sub-sector : Description and evaluation of the overall structure, process and performance of drug quality assurance/control systems at both central and provincial levels; Assessment of the procedures ensuring the quality of drugs and of manufacturing facilities, the thoroughness and frequency of these quality inspections and the overall effectiveness of the quality assurance/control systems; Detailed analysis of all the sources and uses of Drug Control Authority Funds; Development of recommendations to ensure that the systems for drug quality assurance at all levels of the health system in the public and private sectors function efficiently and effectively in the future. Strengthening the Logistics Management and Rational Use of Drugs: Description and analysis of the existing patterns of drug prescription, dispensing and consumption in the public and private sectors. Review of the logistics management system in the public and private sectors and recommendations for strengthening and developing a national procurement and logistics management action plan; Evaluation of the existing policies, norms, standards and practices related to the use of pharmaceuticals by health professionals and consumers; Development of alternative proposals for the establishment of an effective program for rational drug use (including an essential drugs policy and generics strategy).
Year:	2004 - 2005